Evotec SE
EVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001412558
No open-market purchases or sales by Evotec SE insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $9.07M in total; no superinvestor holds it.
Other share classesEVOTF
13F holders, Q1 2023
Institutional positions in Evotec SE as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- −3 vs. Q4 2022
- Shares held
- 1.37M
- −1.23M (−47.3%) vs. Q4 2022
- Total value
- $14.5M
- −$6.53M (−31.0%) vs. Q4 2022
- New holders
- 1
- 3 more added
- Sold out
- 4
- 9 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 34 | $9.07M |
| Q1 2026 | 46 | $20.3M |
| Q4 2025 | 44 | $30.4M |
| Q3 2025 | 37 | $35.9M |
| Q2 2025 | 37 | $40.5M |
| Q1 2025 | 25 | $30.4M |
| Q4 2024 | 26 | $36.9M |
| Q3 2024 | 24 | $29.6M |
| Q2 2024 | 28 | $35.0M |
| Q1 2024 | 20 | $38.7M |
| Q4 2023 | 28 | $66.5M |
| Q3 2023 | 24 | $12.0M |
| Q2 2023 | 20 | $15.4M |
| Q1 2023 | 19 | $14.5M |
| Q4 2022 | 22 | $21.1M |
| Q3 2022 | 22 | $43.5M |
| Q2 2022 | 21 | $57.3M |
| Q1 2022 | 22 | $83.3M |
| Q4 2021 | 20 | $157.3M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Evotec SE; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 17 | $0 | 0.00% | 00.0% | Unchanged |
| Bell Investment Advisors, Inc | 22 | $230 | 0.00% | 00.0% | Unchanged |
| Parallel Advisors, LLC | 70 | $732 | 0.00% | 00.0% | Unchanged |
| Lindbrook Capital, LLC | 72 | $752 | 0.00% | 00.0% | Unchanged |
| Signaturefd, LLC | 144 | $1.50K | 0.00% | −206−58.9% | Reduced |
| US Bancorp | 250 | $2.61K | 0.00% | −178−41.6% | Reduced |
| Washington Trust Co | 421 | $4.40K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 1,330 | $13.9K | 0.00% | −2,006−60.1% | Reduced |
| Bank of America Corp | 4,414 | $46.1K | 0.00% | +483+12.3% | Added |
| BlackRock Inc. | 5,240 | $54.8K | 0.00% | −1,138−17.8% | Reduced |
| FMR LLC | 5,443 | $57.8K | 0.00% | −2,175−28.6% | Reduced |
| DCF Advisers, LLC | 12,388 | $129.5K | 0.10% | +12,388 | New |
| Old Mission Capital LLC | 13,226 | $138.2K | 0.00% | −11,309−46.1% | Reduced |
| Optiver Holding B.V. | 28,075 | $297.9K | 0.01% | +6,599+30.7% | Added |
| Morgan Stanley | 46,796 | $489.0K | 0.00% | +297+0.6% | Added |
| Jane Street Group, LLC | 54,508 | $569.6K | 0.00% | −16,911−23.7% | Reduced |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 215,668 | $2.29M | 0.01% | −7,103−3.2% | Reduced |
| Millennium Management LLC | 234,623 | $2.49M | 0.00% | −2,518−1.1% | Reduced |
| Federated Hermes, Inc. | 750,000 | $7.96M | 0.02% | 00.0% | Unchanged |
| Artal Group S.A. | 0 | $0 | 0.00% | −1,149,425−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −31,509−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −13,284−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −13,238−100.0% | Sold out |